Prostate Cancer

After a drop, the frequency of PSA screening for prostate cancer has stabilized.

Study: To prolong survival in early-stage prostate cancer that is low-risk, observe instead of operating.

A targeted drug for women with ovarian cancer may also benefit men with prostate cancer who have similar genetic mutations. A phase 3 trial is designed to find out.

Jevtana (cabazitaxel) was granted approval by the Food and Drug Administration (FDA) for the treatment of men with metastatic castration-resistant prostate cancer who previously received a docetaxel-containing regimen.

Scientists are looking for more and better ways to identify the prostate cancers that are most likely to become aggressive.

Stroke survivors were diagnosed with cancer at almost double the rate of incidence in the general population, one study showed.

Hall of Fame quarterback Jim Kelly met with CURE to talk about his cancer experience.

For years, people believed that there was a link between vasectomies and prostate cancer.

When it comes to active surveillance and prostate-specific antigen (PSA) screening for localized prostate cancer, the paradigm has been shifting and the debate over which is correct has been raging on in recent years, says Andrew Stephenson, M.D.

This morning, Senate Republican leaders released the draft of a bill to repeal and replace the Affordable Care Act (Obamacare).

Inhibiting the ABCB1 gene with antiandrogen therapy – such as Xtandi (enzalutamide) and Casodex (bicalutamide) – may be the answer to increasing efficiency of tanxane-based therapies.

A new study published in Cancer Medicine examined the long-term health-related effects of definitive treatment for patients with localized prostate cancer and found that they continue more than 10 years after treatment.

Some newly diagnosed patients with prostate cancer reduced their risk of death with earlier use of Zytiga, according to two trials presented at the ASCO Annual Meeting.

After the Affordable Care Act was passed, a study found that there were more stage 1 cancer diagnoses across the nation.

Previously reported declines in prostate-specific antigen testing have not continued in recent years, and that approximately one-third of men age 50 years or older still receive routine PSA tests.

A recent study found that, due to higher incidence of prostate cancer in black man, PSA testing may need to be started earlier in this population, and be done more frequently.

Leonard Gomella, M.D., recommends that healthcare providers familiarize themselves with how each novel biomarker should be used and then decide which one to use for a more individualized approach in clinical practice.

The USPSTF may be changing its stance on PSA screening for prostate cancer.

Androgen deprivation therapy, a popular treatment for prostate cancer, may have a link to dementia, according to a recent analysis.

While other tumor types have seen extraordinary progress with immunotherapy agents such as Opdivo (nivolumab) and Yervoy (ipilimumab), they have not yet shown similar success in the treatment of prostate cancer. Padmanee Sharma, M.D., Ph.D., weighs in.

In an interview with CURE at the Interdisciplinary Prostate Cancer Congress, Celesita Higano, M.D., discussed the early use of chemotherapy, the potential for PARP inhibitors and the evolving role of radium-223 in prostate cancer.

The amount of sleep a man gets can have an impact on prostate cancer outcomes, according to a recent study.

Nerve and other damage from cancer treatments can impair men’s sexual function, and adjusting can be a challenge.

Since it is found in the majority of patients with mCRPC, circulating tumor DNA may be able to lead the way to more personalized prostate cancer care.

Durvalumab and Lynparza (olaparib) provided a response for patients in a small study.